Table 2.
Recombinant TRAIL use in clinical trials.
| Recombinant TRAIL | Disease | Phase | Clinical Trial |
|---|---|---|---|
| Recombinant human Apo-2 ligand for injection | Non-small-cell lung cancer (NSCLC) stage IV | 3 | NCT03083743 |
| Recombinant human TRAIL–trimer fusion protein (SCB-313) | Malignant pleural effusions | 1 | NCT038669697 |
| Peritoneal malignancies | 1 | NCT03443674 | |
| Peritoneal carcinomatosis | 1 | NCT04047771 | |
| rhApo2L/TRAIL (AMG 951) with chemotherapy bevacizumab | Non-small-cell lung cancer (NSCLC) | 2 | NCT00508625 |
| Dulanermin plus rituximab | Non-Hodgkin’s lymphoma | 1, 2 | NCT00400764 |
| Dulanermin plus Camptosar® /Erbitux® or FOLFIRI | Metastatic colorectal cancer | 1 | NCT00671372 |
| Dulanermin with FOLFOX and bevacizumab | Metastatic colorectal cancer | 1 | NCT00873756 |